Pacher Pal, Schulz Richard, Liaudet Lucas, Szabó Csaba
Laboratory of Physiological Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane MSC 9413, Room 2S24, Bethesda, MD 20892-9413, USA.
Trends Pharmacol Sci. 2005 Jun;26(6):302-10. doi: 10.1016/j.tips.2005.04.003.
Dysregulation of nitric oxide (NO) and increased oxidative and nitrosative stress are implicated in the pathogenesis of heart failure. Peroxynitrite is a reactive oxidant that is produced from the reaction of nitric oxide with superoxide anion and impairs cardiovascular function through multiple mechanisms, including activation of matrix metalloproteinases (MMPs) and nuclear enzyme poly(ADP-ribose) polymerase (PARP). Recent studies suggest that the neutralization of peroxynitrite or pharmacological inhibition of MMPs and PARP are promising new approaches in the experimental therapy of various forms of myocardial injury. In this article, the role of nitrosative stress and downstream mechanisms, including activation of MMPs and PARP, in various forms of heart failure are discussed and novel emerging therapeutic strategies offered by neutralization of peroxynitrite and inhibition of MMPs and PARP in these pathophysiological conditions are reviewed.
一氧化氮(NO)失调以及氧化应激和亚硝化应激增加与心力衰竭的发病机制有关。过氧亚硝酸盐是一种活性氧化剂,由一氧化氮与超氧阴离子反应产生,并通过多种机制损害心血管功能,包括激活基质金属蛋白酶(MMPs)和核酶聚(ADP - 核糖)聚合酶(PARP)。最近的研究表明,中和过氧亚硝酸盐或对MMPs和PARP进行药理抑制是各种形式心肌损伤实验性治疗中有前景的新方法。在本文中,讨论了亚硝化应激及其下游机制(包括MMPs和PARP的激活)在各种形式心力衰竭中的作用,并综述了在这些病理生理条件下通过中和过氧亚硝酸盐以及抑制MMPs和PARP提供的新兴治疗策略。